EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis

Caroline Bascoul-Mollevi, Sophie Gourgou, Christophe Borg, Pierre-Luc Etienne, Emmanuel Rio, Eric Rullier, Beata Juzyna, Florence Castan, Thierry Conroy

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.03.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Caroline Bascoul-Mollevi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biometrics Unit, Institut du Cancer Montpellier, Montpellier, France; Institut Desbrest d'Epidémiologie et de Santé Publique, Université de Montpelli…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsRectal NeoplasmsHumansMaleIrinotecanAntineoplastic Combined Chemotherapy ProtocolsOxaliplatinLeucovorinQuality of LifeNeoadjuvant TherapyTreatment OutcomeFluorouracilChemoradiotherapyVomitingNeoplasm Staging

Stichwörter der Autor:innen

Health-related quality of lifeNeoadjuvant chemotherapyPrognostic factorsRectal cancer

Substanzen

folfirinoxIrinotecanOxaliplatinLeucovorinFluorouracil

Autor:innen und Institutionen

  • Biometrics Unit, Institut du Cancer Montpellier, Montpellier, France; Institut Desbrest d'Epidémiologie et de Santé Publique, Université de Montpellier, Inserm, Montpellier, France; French National Platform Quality of L…
  • Biometrics Unit, Institut du Cancer Montpellier, Montpellier, France; French National Platform Quality of Life and Cancer, France.
  • University Hospital of Besançon, CIC-BT1431, Besançon, France.
  • CARIO, Hôpital Privé des côtes d'Armor, Plérin, France.
  • Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France.
  • Centre Hospitalier et Universitaire de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.

Zitieren

APA

Bascoul-Mollevi, C., Gourgou, S., Borg, C., Etienne, P. L., Rio, E., Rullier, E., Juzyna, B., Castan, F., & Conroy, T. (2023). Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.03.021

Vancouver

Bascoul-Mollevi C, Gourgou S, Borg C, Etienne PL, Rio E, Rullier E, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.03.021

BibTeX
@article{BascoulMollevi2023,
  author = {Bascoul-Mollevi, Caroline and Gourgou, Sophie and Borg, Christophe and Etienne, Pierre-Luc and Rio, Emmanuel and Rullier, Eric and Juzyna, Beata and Castan, Florence and Conroy, Thierry},
  title = {Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.03.021}
}
Kostenlos starten →